144 related articles for article (PubMed ID: 32269283)
1. Author Correction: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model.
Singh A; Wilson JW; Schofield CJ; Chen R
Sci Rep; 2020 Apr; 10(1):6041. PubMed ID: 32269283
[TBL] [Abstract][Full Text] [Related]
2. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
3. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
4. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment.
Wang Z; Schley G; Türkoglu G; Burzlaff N; Amann KU; Willam C; Eckardt KU; Bernhardt WM
Nephrol Dial Transplant; 2012 Mar; 27(3):929-36. PubMed ID: 21742784
[TBL] [Abstract][Full Text] [Related]
5. Prolyl-hydroxylase inhibitor activating hypoxia-inducible transcription factors reduce levels of transplant arteriosclerosis in a murine aortic allograft model.
Heim C; Bernhardt W; Jalilova S; Wang Z; Motsch B; Ramsperger-Gleixner M; Burzlaff N; Weyand M; Eckardt KU; Ensminger SM
Interact Cardiovasc Thorac Surg; 2016 May; 22(5):561-70. PubMed ID: 26819270
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases.
Koivunen P; Serpi R; Dimova EY
Pharmacol Res; 2016 Dec; 114():265-273. PubMed ID: 27832958
[TBL] [Abstract][Full Text] [Related]
7. miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning.
Jiao X; Xu X; Fang Y; Zhang H; Liang M; Teng J; Ding X
Nephrology (Carlton); 2017 May; 22(5):366-373. PubMed ID: 27030384
[TBL] [Abstract][Full Text] [Related]
8. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
9. Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
Strowitzki MJ; Cummins EP; Taylor CT
Cells; 2019 Apr; 8(5):. PubMed ID: 31035491
[TBL] [Abstract][Full Text] [Related]
10. Sestrin2 inhibits hypoxia-inducible factor-1α accumulation via AMPK-mediated prolyl hydroxylase regulation.
Seo K; Seo S; Ki SH; Shin SM
Free Radic Biol Med; 2016 Dec; 101():511-523. PubMed ID: 27840318
[TBL] [Abstract][Full Text] [Related]
11. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Sugahara M; Tanaka T; Nangaku M
Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
[TBL] [Abstract][Full Text] [Related]
12. The protective effect of Hif3a RNA interference and HIF-prolyl hydroxylase inhibition on cardiomyocytes under anoxia-reoxygenation.
Drevytska T; Gonchar E; Okhai I; Lynnyk O; Mankovska I; Klionsky D; Dosenko V
Life Sci; 2018 Jun; 202():131-139. PubMed ID: 29660430
[TBL] [Abstract][Full Text] [Related]
13. Adaptive response to hypoxia and remote ischaemia pre-conditioning: a new hypoxia-inducible factors era in clinical medicine.
Heyman SN; Leibowitz D; Mor-Yosef Levi I; Liberman A; Eisenkraft A; Alcalai R; Khamaisi M; Rosenberger C
Acta Physiol (Oxf); 2016 Apr; 216(4):395-406. PubMed ID: 26449466
[TBL] [Abstract][Full Text] [Related]
14. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
Wakashima T; Tanaka T; Fukui K; Komoda Y; Shinozaki Y; Kobayashi H; Matsuo A; Nangaku M
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F14-F24. PubMed ID: 31630548
[TBL] [Abstract][Full Text] [Related]
15. Author Correction: Pro-inflammatory cytokines activate hypoxia-inducible factor 3α via epigenetic changes in mesenchymal stromal/stem cells.
Cuomo F; Coppola A; Botti C; Maione C; Forte A; Scisciola L; Liguori G; Caiafa I; Ursini MV; Galderisi U; Cipollaro M; Altucci L; Cobellis G
Sci Rep; 2020 Apr; 10(1):6776. PubMed ID: 32303693
[TBL] [Abstract][Full Text] [Related]
16. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury.
Billin AN; Honeycutt SE; McDougal AV; Kerr JP; Chen Z; Freudenberg JM; Rajpal DK; Luo G; Kramer HF; Geske RS; Fang F; Yao B; Clark RV; Lepore J; Cobitz A; Miller R; Nosaka K; Hinken AC; Russell AJ
Skelet Muscle; 2018 Nov; 8(1):35. PubMed ID: 30424786
[TBL] [Abstract][Full Text] [Related]
17. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase.
Jeon H; Kim H; Choi D; Kim D; Park SY; Kim YJ; Kim YM; Jung Y
Mol Pharmacol; 2007 Jun; 71(6):1676-84. PubMed ID: 17377063
[TBL] [Abstract][Full Text] [Related]
18. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway.
Shin J; Nunomiya A; Kitajima Y; Dan T; Miyata T; Nagatomi R
Skelet Muscle; 2016; 6():5. PubMed ID: 26949511
[TBL] [Abstract][Full Text] [Related]
19. Prolyl hydroxylase 2 (PHD2) inhibition protects human renal epithelial cells and mice kidney from hypoxia injury.
Fang Y; Zhang H; Zhong Y; Ding X
Oncotarget; 2016 Aug; 7(34):54317-54328. PubMed ID: 27527871
[TBL] [Abstract][Full Text] [Related]
20. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
